IQV: Accelerating organic growth and record R&D bookings drove higher FY2026 guidance

What happened

IQVIA's Q3 revenue, adjusted EBITDA and adjusted EPS beat guidance. Organic growth accelerated and R&D bookings hit a four-year high. The company raised its FY2026 guidance, citing AI adoption, improving demand and stronger win rates.

Confirmed

Global impact / market context

Higher bookings mean more signed future work, which can support revenue later. Raised guidance signals management expects stronger results, which can lift investor expectations for profit and keep spending plans intact.

Analyst inference

The update suggests demand for drug-development services is improving. Companies may spend more on research, which supports IQVIA's revenue and cash available. AI adoption and better win rates could help it capture more of that spending.

Analyst inference

What to watch

1. Watch whether IQVIA delivers the raised FY2026 guidance it issued after Q3 results. Confirmed
2. Track R&D bookings and win rates to see if the four-year-high momentum carries into coming quarters. Proposed
3. Monitor whether AI adoption lowers costs or speeds client work enough to protect profit per sale as demand rises. Analyst inference

Evidence

• Original source link unavailable